ES2602965T3 - Inhibidores de aril lactama quinasa - Google Patents

Inhibidores de aril lactama quinasa Download PDF

Info

Publication number
ES2602965T3
ES2602965T3 ES13744927.8T ES13744927T ES2602965T3 ES 2602965 T3 ES2602965 T3 ES 2602965T3 ES 13744927 T ES13744927 T ES 13744927T ES 2602965 T3 ES2602965 T3 ES 2602965T3
Authority
ES
Spain
Prior art keywords
mmol
alkyl
retention time
oxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13744927.8T
Other languages
English (en)
Spanish (es)
Inventor
Vivekananda M. Vrudhula
Senliang Pan
Ramkumar Rajamani
Susheel Jethanand NARA
Maheswaran Sivasamban KARATHOLUVHU
Tarun Kumar MAISHAL
Jonathan L. Ditta
Carolyn Diane Dzierba
Joanne J. Bronson
John E. Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2602965T3 publication Critical patent/ES2602965T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES13744927.8T 2012-07-31 2013-07-24 Inhibidores de aril lactama quinasa Active ES2602965T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261677856P 2012-07-31 2012-07-31
US201261677856P 2012-07-31
US201313946344 2013-07-19
US13/946,344 US8901305B2 (en) 2012-07-31 2013-07-19 Aryl lactam kinase inhibitors
PCT/US2013/051831 WO2014022167A1 (en) 2012-07-31 2013-07-24 Aryl lactam kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2602965T3 true ES2602965T3 (es) 2017-02-23

Family

ID=50026068

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13744927.8T Active ES2602965T3 (es) 2012-07-31 2013-07-24 Inhibidores de aril lactama quinasa

Country Status (12)

Country Link
US (1) US8901305B2 (cg-RX-API-DMAC7.html)
EP (1) EP2880032B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015528018A (cg-RX-API-DMAC7.html)
CN (1) CN104507941A (cg-RX-API-DMAC7.html)
AR (1) AR093758A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015001890A2 (cg-RX-API-DMAC7.html)
CA (1) CA2880523A1 (cg-RX-API-DMAC7.html)
EA (1) EA201590268A1 (cg-RX-API-DMAC7.html)
ES (1) ES2602965T3 (cg-RX-API-DMAC7.html)
MX (1) MX2015000980A (cg-RX-API-DMAC7.html)
TW (1) TW201410676A (cg-RX-API-DMAC7.html)
WO (1) WO2014022167A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509066A (ja) 2013-02-22 2016-03-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アダプター関連キナーゼ１（ａａｋ１）の阻害剤としての５ｈ−クロメノ［３，４−ｃ］ピリジン
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US9737542B2 (en) 2013-10-11 2017-08-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20160333006A1 (en) * 2014-01-29 2016-11-17 Bristol-Myers Squibb Company Aryl lacta kinase inhibitors
HRP20181899T1 (hr) 2014-04-02 2019-01-11 Bristol-Myers Squibb Company Biaril inhibitori kinaze
ES2740224T3 (es) * 2015-04-10 2020-02-05 Bristol Myers Squibb Co 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
US10246469B2 (en) 2015-10-01 2019-04-02 Bristol-Myers Squibb Company Biaryl kinase inhibitors
US10544120B2 (en) 2015-10-01 2020-01-28 Bristol-Myers Squibb Company Biaryl kinase inhibitors
EP4010081A4 (en) * 2019-08-08 2023-07-26 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center POLYTHERAPY FOR THE TREATMENT OF CANCER
CN114853664B (zh) * 2022-06-02 2023-09-29 河南大学 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法
CN116102542A (zh) * 2023-02-15 2023-05-12 如东众意化工有限公司 环丙唑醇精制母液中环丙唑醇的回收方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
RU95113454A (ru) 1992-12-02 1997-06-10 Пфайзер Инк. (US) Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
WO2003086325A2 (en) 2002-04-05 2003-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
EP1593667A4 (en) 2003-02-12 2009-03-04 Takeda Pharmaceutical Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
CA2555287A1 (en) * 2004-02-18 2005-08-25 David Garrett Loughhead Heterocyclic gaba-a subtype selective receptor modulators
JP2008504276A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
AU2006326247A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
CA2645031A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
IN2014KN02423A (cg-RX-API-DMAC7.html) 2006-04-07 2015-05-01 Vertex Pharma
WO2008022154A2 (en) 2006-08-14 2008-02-21 Wyeth Methods of identifying agents for treating neurological disorders
EA200900799A1 (ru) * 2006-12-22 2009-12-30 Новартис Аг Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями
JP2012526844A (ja) * 2009-05-15 2012-11-01 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション Ｍｃｉおよびアルツハイマー病の処置
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
US8791257B2 (en) * 2010-03-31 2014-07-29 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
EP3235499A3 (en) 2012-03-09 2018-01-17 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
MX347917B (es) 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
PT2834243T (pt) 2012-03-09 2018-08-01 Lexicon Pharmaceuticals Inc Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização

Also Published As

Publication number Publication date
MX2015000980A (es) 2015-04-10
US8901305B2 (en) 2014-12-02
EP2880032B1 (en) 2016-10-05
BR112015001890A2 (pt) 2017-07-04
CA2880523A1 (en) 2014-02-06
TW201410676A (zh) 2014-03-16
EA201590268A1 (ru) 2015-05-29
US20140038999A1 (en) 2014-02-06
JP2015528018A (ja) 2015-09-24
CN104507941A (zh) 2015-04-08
WO2014022167A1 (en) 2014-02-06
EP2880032A1 (en) 2015-06-10
AR093758A1 (es) 2015-06-24

Similar Documents

Publication Publication Date Title
ES2602965T3 (es) Inhibidores de aril lactama quinasa
ES2885432T3 (es) Derivados de imidazol pentacíclicos condensados
KR102411532B1 (ko) 엔도솜 톨-유사 수용체의 억제제로서의 화합물 및 조성물
JP6335172B2 (ja) テノホビルプロドラッグおよびその医薬用途
ES2582315T3 (es) Derivado de ftalazinona-cetona, método de preparación de la misma y uso farmacéutico de la misma
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
ES2624263T3 (es) Azaindoles en calidad de agentes antivirales del virus sincitial respiratorio
CA3093527A1 (en) Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
ES2685661T3 (es) Derivado de pirrolopirimidina
IL256375A (en) New histological histories, process for their preparation and pharmaceutical preparations containing them
JP6487527B2 (ja) スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）
ES2642762T3 (es) Inhibidores de fosfolipasa A2 asociada a lipoproteínas (LP-PLA2) basados en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1H)-ona
CA2901868C (en) Dihydropyridazine-3,5-dione derivative
CA3115643A1 (en) Amino acid compounds and methods of use
IL297969A (en) Treatment of respiratory diseases with amino acid compounds
CN118434747A (zh) 一种含氮杂环化合物、其制备方法、中间体及应用
JP7731895B2 (ja) モノアシルグリセロールリパーゼ調節因子
ES2987356T3 (es) Compuestos antiproliferación y usos de los mismos
ES2922029T3 (es) Análogos de hexahidropirimidina antimalaria
CN118382625A (zh) 作为TLR7/8激动剂的吡啶[4,3-d]嘧啶类化合物
JP2023522863A (ja) Ｅｇｆｒ阻害剤としての三環式化合物
TW202237577A (zh) 化合物、組合物及方法
EP4192836A1 (en) Atr inhibitors and uses thereof
ES2881611T3 (es) Producto farmacéutico que contiene inhibidor del transportador de fosfato dependiente de sodio
ES2740224T3 (es) 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)